Juan Antonio
Pineda Vergara
Publications by the researcher in collaboration with Juan Antonio Pineda Vergara (41)
2016
2015
-
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: A randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents
HIV Clinical Trials, Vol. 16, Núm. 2, pp. 72-80
-
IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection
AIDS
-
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5
-
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5
2014
-
A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers
Liver International, Vol. 34, Núm. 4, pp. 558-566
-
IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
PLoS ONE, Vol. 9, Núm. 4
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy
Journal of Infection, Vol. 68, Núm. 4, pp. 372-377
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2013
-
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921
-
Chronic hepatitis e in HIV patients: Rapid progression to cirrhosis and response to oral ribavirin
Clinical Infectious Diseases, Vol. 57, Núm. 3, pp. 465-468
-
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435
-
Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves
Journal of Medical Virology, Vol. 85, Núm. 10, pp. 1734-1740
-
Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response
Journal of Infection, Vol. 67, Núm. 1, pp. 59-64
-
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
AIDS, Vol. 27, Núm. 1, pp. 81-85
-
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection
AIDS, Vol. 27, Núm. 17, pp. 2715-2724
2012
-
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
Retrovirology, Vol. 9
-
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial
Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968
-
Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b
Journal of Acquired Immune Deficiency Syndromes, Vol. 60, Núm. 2, pp. 117-123